From our point, ROS scavengers as well as mitoprotective strategies might be one part of a complex treatment strategy for AD also comprising drugs lowering
the early oligomeric Aß species which all need to be applied decades before the disease is diagnosed.
Furthermore, in brains from APP transgenic mice conformation - specific antibodies have revealed the
early appearance of intraneuronal fibrillar and
oligomeric Aβ immunoreactivity, which declined as amyloid plaques appeared, and further became evident in the extracellular space [10].